Inhibrx Biosciences, Inc. · NASDAQ:INBX
Inhibrx Biosciences — Investor Presentation (November 2022)
46 slides from Inhibrx Biosciences's investor presentation, November 2022
Slide 1: Innovation Driven Outcomes Focused
Innovation Driven Outcomes Focused November 2022
Slide 2: Presentation disclaimer
Presentation disclaimer Commission filings, including those described in our Annual Report on Form 10-K as This presentation contains forward-looking statements. In some cases, you can identify well as our Quarterly Reports on Form 10-Q, and supplemented from time to time by forward-looking statemen
Slide 3: The Candidates
REGISTRATION- THE CANDIDATES PRECLINICAL PHASE 1 ENABLING Pivotal Trial Enrolling + Potential path to approval in chondrosarcoma by 2025 with potential profitability in 2026; INBRX-109 potential for $600M in U.S. sales within 3 years of launch Our Tetravalent DR5 Agonist + Initial combination cohort
Slide 4: Anchored by innovation and protein-engineering expertise
Anchored by innovation and protein-engineering expertise Expertise Inhibrx’s modular sdAb platform Technology Experienced leadership team + Ability to precision engineer with proven to specific target biology innovation and Strategy + Smaller than conventional All platforms and execution antibodies
Slide 5: Partnerships with industry leaders
Partnerships with industry leaders PARTNER FOCUS ECONOMICS Development and regulatory Key financial CD47 checkpoint inhibitor milestones of up to $934 million + royalties highlights Option to Ex-North America rights Option exercise fee $12.5M to INBRX-101 AATD $290M Cash Use of INBX sdAb platform fo
Slide 6: Near term expected clinical milestones
Near term expected clinical milestones INBRX-101 INBRX-109 INBRX-109 (AATD) Potential (DR5) Initial start to registration (DR5) mesothelioma, Registration- trial Ewing sarcoma, INBRX-101 enabling Phase 2 pancreatic cancer, Chondrosarcoma (GvHD) Potential colorectal cancer start to registration data
Slide 7: INBRX-101
INBRX-101 Recombinant Alpha-1 Antitrypsin Fc-fusion Protein
Slide 8: INBRX-101 Alpha-1 Antitrypsin Deficiency (AATD)
INBRX-101 Alpha-1 Antitrypsin Deficiency (AATD)
Slide 9: Functional AAT levels in healthy individuals vs. AATD patients
Functional AAT levels in healthy individuals vs. AATD patients 80 Disease history + Alpha-1 antitrypsin deficiency (AATD) is an inherited orphan 60 respiratory disease characterized by deficient levels of alpha-1 Functional AAT levels (μM) antitrypsin (AAT) + This causes loss of lung function and de
Slide 10: Current standard of care does not maintain normal AAT levels
Current standard of care does not maintain normal AAT levels + INBRX-101 dosed every four weeks at 120 Functional AAT serum levels at steady-state (INBRX-101 vs. pdAAT) mg/kg is predicted to maintain patients above the lower threshold of the normal range and 80 achieve an average level (Cavg) of fun
Slide 11: Potential advantages of recombinant AAT Fc-fusion protein INBRX-101
Potential advantages of recombinant AAT Fc-fusion protein INBRX-101 Potential to extend the dosing interval from weekly to monthly AAT Has demonstrated potential to maintain patients in normal functional AAT range Fc Recombinant manufacturing provides abundant supply with no pathogen risk 11
Slide 12: INBRX-101 topline results from Phase 1
INBRX-101 - Topline results from Phase 1, Part 2 PART 2 INBRX-101 topline results – Multiple ascending 3rd dose of 40, 80 or 120 mg/kg (Q3W) 100 dose escalation (MAD) 120 mg/kg Complete Functional AAT levels (μM) 80 80 mg/kg N=18 40 mg/kg 60 N=6 40 mg/kg 40 N=6 80 mg/kg* 20 N=6 120 mg/kg* 0 Baseline
Slide 13: INBRX-101 is present in the lung in every patient sampled
INBRX-101 is present in the lung in every patient sampled following IV dosing Bronchoalveolar lavage fluid (BALF) sample collection and analysis 200 + BALF samples were collected from 3 lobes of the lung for each patient in the 80 (N = 5)1 and 120 (N = 6) mg/kg MAD cohorts prior to dosing and two we
Slide 14: INBRX-101 potential for ~$3B annual U.S. revenue in AATD
INBRX-101 has the potential to achieve ~$3B in annual U.S. revenue with expected rapid uptake in patients with severe AATD INBRX-101 top line projected U.S. sales & key assumptions $3.0B $3B Key assumptions + “Severe (ZZ/SZ)” AATD patients (same as pdAATs today) + 7% CAGR throughout forecast period
Slide 15: INBRX-101 could shift the treatment paradigm in AATD
INBRX-101 has the potential to shift the treatment paradigm, expanding augmentation therapy to a broad group of AATD patients in the U.S. TODAY FUTURE PI*ZZ or PI*SZ PI*ZZ or PI*SZ U.S. prevalence ~100K ~100K (same as today) ~40% (driven by increased Treatment rate ~8-10% diagnosis rates) Total trea
Slide 16: INBRX-101 Graft versus Host Disease (GvHD)
INBRX-101 Graft versus Host Disease (GvHD)
Slide 17: Strong clinical data and established guidelines for AAT therapy in acute GVHD
Strong clinical data and established guidelines exist for AAT therapy in acute GVHD Existing clinical data for Jakafi: Existing clinical data for plasma-derived AAT therapies current standard of care 2L (steroid resistant) aGVHD Two active Phase 2/3 2L (steroid resistant) acute GVHD (aGVHD) Ruxoliti
Slide 18: INBRX-101 potential in acute GVHD and prophylaxis, >$1bn U.S.
INBRX-101 has the potential for fast entry into Acute GVHD, expanding to Prophylaxis, achieving >$1bn in the US Market INBRX-101 acute & prophylaxis GvHD top line projected US sales & key assumptions Key assumptions: Potential advantages over pdAAT $1,300M $1,200 + TPP: Superior safety, efficacious
Slide 19: INBRX-101 GvHD expansion opportunities
INBRX-101 GvHD expansion opportunities U.S. chronic GvHD – progression beyond steroids Prophylaxis, acute, & chronic GvHD – EU / Japan US Prevalence (2022) ~16,000 6 ~$2bn >$3bn Extensive disease requiring Europe & Japan 21,000 2, 3 2030 EU & JP 8,000 2030 US Market Allogeneic Transplants therapy (5
Slide 20: INBRX-109 Tetravalent DR5 Agonist
INBRX-109 Tetravalent DR5 Agonist
Slide 21: Tetravalent DR5 agonist
Tetravalent DR5 agonist DR5: sdAb DR5: sdAb + Death receptor 5 (DR5) is a receptor DR5: sdAb DR5: sdAb for the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) + DR5 activation naturally eliminates damaged and neoplastic cells Fc: effector function disabled 105 kDa 21
Slide 22: Preliminary Phase 1 data in conventional chondrosarcoma
Preliminary Phase 1 data in unresectable or metastatic conventional chondrosarcoma 3mo 6mo 9mo 12mo 15mo 18mo SD (-11%) SD (-1%) IDH ► SD (-17%) SD (-20%) IDH SD (-7%) SD (-13%) IDH ► PR (-60%) SD (10%) SD (-19%) IDH ► SD (-13%) SD (5%) SD (-8%) IDH ► SD (3%) SD (-23%) IDH PR (-45%) SD (-4%) SD (16%
Slide 23: INBRX-109 Phase 2 registration-enabling study design in chondrosarcoma
INBRX-109 Phase 2 potentially registration-enabling study design in chondrosarcoma ENDPOINTS Randomization INBRX-109 Placebo Primary: Progression free Conventional chondrosarcoma, Grades Initiated survival 1, 2 and 3, unresectable or metastatic N=134* N=67 * Secondary: Overall survival, quality of l
Slide 24: Chondrosarcoma patient pool of ~2.5K in the U.S.
Many patients with local disease eventually progress to unresectable or metastatic chondrosarcoma, providing an annual prevalent patient pool of ~2.5K in the U.S. Conventional chondrosarcoma patient flow Unresectable or metastatic population (opportunity at launch) Legend: Peri-operative opportunity
Slide 25: INBRX-109 potential for ~$1B annual revenue
Based on current trends and lack of approved options, INBRX-109 has the potential to achieve ~$1B in annual revenue with rapid uptake post launch INBRX-109 top line projected U.S. sales in the unresectable/metastatic setting & key assumptions $1.0B $1B Key assumptions + ~375K* annual price per patie
Slide 26: INBRX-109 on the horizon
INBRX-109 on the horizon PART 3 POTENTIAL FUTURE Combination studies Ongoing OPPORTUNITIES Pancreatic adenocarcinoma N=20 2nd line with mFOLFIRI Solid tumors + IAP antagonists Ewing sarcoma with N=20 Irinotecan + Temozolomide Hematologic tumors + Bcl-2 inhibitors Colorectal Cancer with N=20 FOLFIRI
Slide 27: INBRX-105 PD-L1 x 4-1BB Multispecific
INBRX-105 PD-L1 x 4-1BB Multispecific
Slide 28: PD-L1 x 4-1BB multispecific
PD-L1 x 4-1BB multispecific PD-L1: sdAb PD-L1: sdAb + Designed to provide spatially-restricted 4-1BB agonism at sites of PD-L1 expression + Highly expressed on tumor infiltrating immune 4-1BB: sdAb 4-1BB: sdAb cells, 4-1BB signaling promotes prolonged T-cell survival memory formation + Constitutive
Slide 29: INBRX-105 is a potential best-in-class 4-1BB agonist
INBRX-105 is a potential best-in-class 4-1BB agonist PD-L1 x 4-1BB Bispecifics CANDIDATE FORMAT 4-1BBL BLOCKING INBRX-105 Bivalent/Bivalent No Gen-1064 Monovalent/Monovalent n/a MCLA-145 Monovalent/Monovalent Yes FS222 Bivalent/Bivalent n/a PRS-343 Bivalent/Bivalent No ND021 Monovalent/Monovalent n/
Slide 30: INBRX-105 Phase 1 trial design
INBRX-105 has the potential to be the first 4-1BB agonist with a robust therapeutic window Phase 1 trial design PART 1 PART 2 PART 3 PART 4 Complete Ongoing Complete Ongoing Single agent dose escalation Single agent dose expansion Dose escalation with Keytruda™ Dose expansion with Keytruda™ N=32 N=3
Slide 31: INBRX-106 Hexavalent OX40 Agonist
INBRX-106 Hexavalent OX40 Agonist
Slide 32: Hexavalent OX40 agonist
Hexavalent OX40 agonist OX40: sdAb OX40: sdAb OX40 is a co-stimulatory receptor on activated T-cells designed to: OX40: sdAb OX40: sdAb + Provide co-stimulation to activated T-cells + Reverse regulatory T-cell induced OX40: sdAb OX40: sdAb immune suppression + Enhance T-cell functionality Fc + Provi
Slide 33: INBRX-106 is a best-in-class OX40 agonist
INBRX-106 is a best-in-class OX40 agonist CANDIDATES VALENCY ISOTYPE LIGAND BLOCKING STATUS INBRX-106 Hexa- IgG1 N Ph 1 (2019) Bivalent anti- INBRX-106 OX40 Hexavalent MOXR-0916 Discontinued GSK-3174998 Discontinued OX40 OX40 BMS-986178 Ph 1 (2016) INCAGN-1949 Bi- IgG1 Y Ph 1 (2016) ABBV-368 Ph 1 (H
Slide 34: Phase 1 INBRX-106 trial as single agent and with Keytruda
Phase 1 INBRX-106 trial as a single agent and in combination with Keytruda Single agent In combination PART 1 PART 2 PART 3 PART 4 INBRX-106 single-agent Complete INBRX 106 single-agent Complete Dose escalation Complete Dose expansion Ongoing dose escalation dose expansion with Keytruda with Keytrud
Slide 35: Market opportunity for INBRX-106 and INBRX-105
Market opportunity for INBRX-106 and INBRX-105 PD-1/PD-L1 WW Revenue PD-1/PD-L1 WW Revenue by Indication (in $ billions) (in $ billions) $70 $63.5 NSCLC 2020 2020 Projected 2026 $60 Melanoma Renal cell $50 carcinoma Bladder cancer $40 Head & neck cancers $30 $27.1 $28.2 Gastrointestinal adenocarcino
Slide 36: INBRX-121 NKp46 Targeted Detuned IL-2
INBRX-121 NKp46 Targeted Detuned IL-2
Slide 37: Affinity differential enables directed IL-2 expansion
Affinity differential enables directed IL-2 expansion/enhancement of specific cell types High affinity sdAb sdAb High affinity antibody targeting INHIBRX has developed sdAbs to an extensive number of antigens + T-cell or NK cell subsets + Activating/co-stimulatory receptors Fc – effector function + Inh
Slide 38: Molecular Targeted Cytokine (MTC) Platform
Molecular Targeted Cytokine (MTC) Platform A Targeted Detuned IL-2 Platform
Slide 39: INBRX-121 expanded the NK cell population and enhanced cytotoxicity
INBRX-121 expanded the NK cell population and enhanced cytotoxicity NKp46 sdAb NKp46 sdAb + NKp46 is an NK-specific marker that maintains expression on tumor-infiltrating NK cells Fc – effector function + Proprietary IL2-X engineering disabled ensures specific modulation of NK Cells without impacting
Slide 40: INBRX-121 poised to bring NK cells to the forefront of immunotherapy
INBRX-121 is poised to bring NK cells to the forefront of immunotherapy Improved NK Activity Safety with durability Multiple potential paths forward INBRX-121 NK NK Single agent NK NK Activated NK cells NK NK CYTOKINES exhibit immediate NK NK NK cytotoxicity NK INBRX-121 Combination therapy ⁺ Expand
Slide 41: Expanded mouse NK cells and enhanced their cytotoxic potential
Expanded mouse NK cells and enhanced their cytotoxic potential NK cell expansion NK cell activation NK cell cytolytic activity 25 5,000 20,000 Max. fold-change (relative to vehicle) 20 4,000 15,000 Granzyme B levels 15 3,000 KLRG1 levels 10,000 10 2,000 5,000 5 1,000 0 0 0 NK cells CD8 T cells Tregs
Slide 42: Synergized with approved therapeutic antibodies
Synergized with approved therapeutic antibodies Raji tumor growth 2,000 Vehicle 1,500 INBRX-121 Tumor Volume (mm3) 1,000 Rituxan INBRX-121 synergized with Rituxan® INBRX-121 + Rituxan in a subcutaneous 500 Raji tumor model resulting in complete 0 tumor regression 0 7 14 21 28 35 42 Dosing Time (days
Slide 43: INBRX-121 safely expanded NK cells in non-human primates
INBRX-121 safely expanded NK cells in non-human primates NK cell expansion in blood after NK Expanded NK cells a single dose of INBRX-121 at 1 mg/kg: NK in a dose-dependent NK NK manner (up to 12-fold) Frequency of lymphocytes NK NK NK NK that persists for more than Pre-dose Day 10 NK 21 days and ca
Slide 44: Expanded NK cells from lymphoma patients
Expanded NK cells from Lymphoma patients IL-2 signaling in patient NK cells Patient NK cell proliferation 60 60 % pSTAT5 positive 40 40 % Ki67 positive 20 20 0 0 INBRX-121 - + - + - + - + INBRX-121 - + - + - + - + DLBCL MCL FL Healthy DLBCL MCL FL Healthy Donor Donor NK cells from Lymphoma patients
Slide 45: Expanded NK cells while enhancing cytotoxic capacities
Expanded the number of NK cells while enhancing their individual cytotoxic capacities 120 100 80 %Target celldeath Anti-hCD20-hlgG1 only INBRX-121 increased NK 60 Anti-hCD20-hlgG1 + cell-mediated killing of 40 INBRX-121 Raji cells in the presence of a Rituximab sequence 20 analog (Anti-hCD20- hIgG1)
Slide 46: Contact: La Jolla, CA
11025 N. Torrey Pines Rd Ste 200 La Jolla, CA 92037 www.inhibrx.com
Inhibrx Biosciences — Investor Presentation (November 2022) on 6ix